Marcus McFerren, MD
Dermatology · Orange, CTNPI 1891971651
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $767,055 of the $871,828 with a category attached, or 88.0%. 40 manufacturers reported payments, led by Lilly USA, LLC at 31.9% of the total. Among dermatology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,774 payments — averaging $491.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$278K
- Sanofi$173K
- Dermavant Sciences, Inc.$89K
- Pfizer$81K
- AbbVie$80K
- Amgen$76K
- plus $95K from 34 others
What the payments were for
- Consulting fees$26,5693%
- Speaking & faculty fees$767,05588%
- Travel & lodging$43,5785%
- Food & beverage$33,5534%
- Education$1,0730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$871,828 in reported general payments places this provider in the 95th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 97 | $381,858 |
| Skyrizi PenRisankizumab-Rzaa | 13 | $294,870 |
| Taltz AutoinjectorIxekizumab | 38 | $272,080 |
| Humira(Cf) PenAdalimumab | 16 | $180,431 |
| Dupixent SyringeDupilumab | 21 | $78,178 |
| Halobetasol Propionate | 78 | $3,829 |
| Clobetasol Propionate | 118 | $3,654 |
| Tacrolimus | 20 | $2,385 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 54 | $1,747 |
| Triamcinolone Acetonide | 196 | $1,661 |
| Metronidazole | 35 | $1,620 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 21 | $1,446 |
| CiclopiroxCiclopirox Olamine | 74 | $1,330 |
| Clindamycin-Benzoyl PeroxideClindamycin Phos/Benzoyl Perox | 12 | $1,308 |
| Ketoconazole | 122 | $1,262 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Orange
- Michael PayetteCromwell$3.2M
- Bruce StroberCromwell$2.9M
- Brett KingFairfield$2.5M
- Mona ShahriariCromwell$2.2M
- Jeremy MossMadison$2M
- Brittany CraiglowFairfield$1.9M
- Meagen McCuskerEnfield$1.8M
- Christopher BunickNew Haven$661K
- Keith ChoateNew Haven$362K
- Kim NicholsGreenwich$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.